Sorafenib ameliorates bleomycin-induced pulmonary fibrosis: Potential roles in the inhibition of epithelial-mesenchymal transition and fibroblast activation

Cell Death and Disease

Volumn 4, Issue 6, 2013, Pages

  Chen, Y L ^a   Zhang, X ^b   Bai, J ^a   Gai, L ^b   Ye, X L ^c   Zhang, L ^b   Xu, Q ^a   Zhang, Y X ^b   Xu, L ^a   Li, H P ^b   Ding, X ^a  

^a INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^b TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^c NINGBO UNIVERSITY   (China)

Author keywords

EMT; fibroblast activation; pulmonary fibrosis; sorafenib; TGF signaling

Indexed keywords

BLEOMYCIN; COLLAGEN; SORAFENIB; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL PROLIFERATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; FIBROSING ALVEOLITIS; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG ALVEOLUS EPITHELIUM; LUNG FIBROBLAST; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RAT;

MUS;

EID: 84879682510     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.154     Document Type: Article

References (45)

1. Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 157: 199-203.
2. King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet 2011; 378: 1949-1961.
3. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006; 174: 810-816.
4. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK et al. ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
5. Iwano M, Plieth D, Danoff TM, Xue C, Okada H, Neilson EG. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 2002; 110: 341-350.
6. Willis BC, Liebler JM, Luby-Phelps K, Nicholson AG, Crandall ED, du Bois RM et al. Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. Am J Pathol 2005; 166: 1321-1332.
7. Kim KK, Kugler MC, Wolters PJ, Robillard L, Galvez MG, Brumwell AN et al. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc Natl Acad Sci USA 2006; 103: 13180-13185.
8. Selman M, Pardo A. Role of epithelial cells in idiopathic pulmonary fibrosis: from innocent targets to serial killers. Proc Am Thorac Soc 2006; 3: 364-372.
9. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000; 342: 1350-1358.
10. Thiery JP, Acloque H, Huang RYJ, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-890.
11. Massagué J, Chen YG. Controlling TGF-beta signaling. Genes Dev 2000; 14: 627-644.
12. Padua D, Massagué J. Roles of TGF-b in metastasis. Cell Res 2009; 19: 89-102.
13. Miettinen PJ, Ebner R, Lopez AR, Derynck R. TGF-b induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. J Cell Biol 1994; 27: 2021-2036.
14. Zavadil J, Bottinger EP. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 2005; 24: 5764-5774.
15. Phan SH. Biology of fibroblasts and myofibroblasts. Proc Am Thorac Soc 2008; 5: 334-337.
16. Khalil N, O'Connor RN, Unruh HW, Warren PW, Flanders KC, Kemp A et al. Increased production and immunohistochemical localization of transforming growth factor-beta in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 1991; 5: 155-162.
17. Khalil N, Parekh TV, O'Connor R, Antman N, Kepron W, Yehaulaeshet T et al. Regulation of the effects of TGF-beta 1 by activation of latent TGF-beta 1 and differential expression of TGF-beta receptors (T beta R-I and T beta R-II) in idiopathic pulmonary fibrosis. Thorax 2001; 56: 907-915.
18. Chen YL, Lv J, Ye XL, Sun MY, Xu Q, Liu CH et al. Sorafenib inhibits transforming growth factor b1-mediated epithelial-mesenchymal transition and apoptosis in mouse hepatocytes. Hepatology 2011; 53: 1708-1718.
19. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M et al. TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134.
20. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
21. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-7109.
22. Kasai H, Allen JT, Mason RM, Kamimura T, Zhang Z. TGF-b1 induces human alveolar epithelial to mesenchymal cell transition (EMT). Respir Res 2005; 6: 56.
23. Cho HJ, Baek KE, Saika S, Jeong MJ, Yoo J. Snail is required for transforming growth factor-beta-induced epithelial-mesenchymal transition by activating PI3 kinase/Akt signal pathway. Biochem Biophys Res Commun 2007; 353: 337-343.
24. Vancheri C, Failla M, Crimi N, Raghu G. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J 2010; 35: 496-504.
25. Cheng S, Lovett DH, Gelatinase A. (MMP-2) is necessary and sufficient for renal tubular cell epithelial-mesenchymal transformation. Am J Pathol 2003; 162: 1937-1949.
26. Nakao A, Fujii M, Matsumura R, Kumano K, Saito Y, Miyazono K et al. Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice. J Clin Invest 1999; 104: 5-11.
27. Chen YF, Feng JA, Li P, Xing D, Zhang Y, Serra R et al. Dominant negative mutation of the TGF-b receptor blocks hypoxia-induced pulmonary vascular remodeling. J Appl Physiol 2006; 100: 564-571.
28. Abe K, Toba M, Alzoubi A, Koubsky K, Ito M, Ota H et al. Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats. Am J Respir Cell Mol Biol 2011; 45: 804-808.
29. Mejias M, Garcia-Pras E, Tiani C, Miquel R, Bosch J, Fernandez M. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology 2009; 49: 1245-1256.
30. Reiberger T, Angermayr B, Schwabl P, Rohr-Udilova N, Mitterhauser M, Gangl A et al. Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats. J Hepatol 2009; 51: 865-873.
31. Wang Y, Gao J, Zhang D, Zhang J, Ma J, Jiang H. New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis. J Hepatol 2010; 53: 132-144.
32. Wu Z, Yang L, Cai L, Zhang M, Cheng X, Yang X et al. Detection of epithelial to mesenchymal transition in airways of a bleomycin induced pulmonary fibrosis model derived from an alpha-smooth muscle actin-Cre transgenic mouse. Respir Res 2007; 8: 1-11.
33. Tanjore H, Xu XC, Polosukhin VV, Degryse AL, Li B, Han W et al. Contribution of epithelialderived fibroblasts to bleomycin-induced lung fibrosis. Am J Respir Crit Care Med 2009; 180: 657-665.
34. Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 2008; 14: 818-829.
35. Bechtel W, McGoohan S, Zeisberg EM, Mü ller GA, Kalbacher H, Salant DJ et al. Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat Med 2010; 16: 544-550.
36. Chang YS, Adnane J, Trail PA, Levy J, Henderson A, Xue D et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 2007; 59: 561-574.
37. Sebolt-Leopold JS, English JM. Mechanisms of drug inhibition of signalling molecules. Nature 2006; 441: 457-462.
38. Daniels CE, Wilkes MC, Edens M, Kottom TJ, Murphy SJ, Limper AH et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-b and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004; 114: 1308-1316.
39. Neef M, Ledermann M, Saegesser H, Schneider V, Reichen J. Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis. J Hepatol 2006; 45: 786-796.
40. Chaudhary NI, Roth GJ, Hilberg F, Mü ller-Quernheim J, Prasse A, Zissel G et al. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J 2007; 29: 976-985.
41. Tugues S, Fernandez-Varo G, Muñoz-Luque J, Ros J, Arroyo V, Rodés J et al. Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology 2007; 46: 1919-1926.
42. Daniels CE, Lasky JA, Limper AH, Mieras K, Gabor E, Schroeder DR. Imatinib-IPF Study Investigators. Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebocontrolled trial results. Am J Respir Crit Care Med 2010; 181: 604-610.
43. Abraham V, Chou ML, DeBolt KM, Koval M. Phenotypic control of gap junctional communication by cultured alveolar epithelial cells. Am J Physiol 1999; 276: L825-L834.
44. Chen YL, Liu B, Zhou ZN, Hu RY, Fei C, Xie ZH et al. Smad6 inhibits the transcriptional activity of Tbx6 by mediating its degradation. J Biol Chem 2009; 284: 23481-23490.
45. Jamall IS, Finelli VN, Que Hee SS. A simple method to determine nanogram levels of 4-hydroyproline in biological tissues. Anal Biochem 1981; 112: 70-75.